Trial
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
A 35-week trial testing whether brenipatide injections improve symptoms and are safe in patients with IBS-diarrhea compared to placebo.
No directly tagged education is live for Dermatology yet. Use the specialty context below plus relevant cross-specialty education while the dedicated hub is expanded.
Use the specialty context and cross-specialty learning below while dedicated modules, podcasts and webinars are added.
A 35-week trial testing whether brenipatide injections improve symptoms and are safe in patients with IBS-diarrhea compared to placebo.
Early-stage trial testing new drug SYX-5219 for safety and effectiveness in healthy people and atopic dermatitis patients.
52-week trial testing whether continuing or increasing ritlecitinib dosing maintains or improves skin pigmentation recovery in non-segmental vitiligo patients.
Trial testing whether a yeast-based spray reduces underarm odor compared to placebo in healthy adults.
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL Surveillance safety signals, cardiovascular…
JAK inhibitors target the JAK-STAT pathway, interrupting intracellular cytokine signalling across several inflammatory diseases. ORAL Surveillance reshaped risk assessment after higher rates…